Trial Profile
Phase II study of oxaliplatin plus bevacizumab salvage chemotherapy in patients with germ cell tumours
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Oxaliplatin (Primary)
- Indications Germ cell cancer
- Focus Therapeutic Use
- 26 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 18 Sep 2014 According to ClinicalTrials.gov record, planned End Date changed from 1 Oct 2013 to 1 Oct 2015.
- 09 Feb 2012 Planned end date changed from 1 Dec 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.